Fulminant myocarditis after the second dose of COVID‐19 mRNA vaccination. Issue 2 (7th February 2022)

• Record Type: Journal Article
• Authors: Oka, Akihiro; Sudo, Yuya; Miyoshi, Toru; Ozaki, Masatomo; Kimura, Yuta; Takagi, Wataru; Ugawa, Satoko; Okada, Tomoaki; Nosaka, Kazumasa; Doi, Masayuki
• Is Part Of: Clinical case reports. Volume 10:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-07
• Subjects: COVID‐19 mRNA vaccination -- fulminant myocarditis -- steroid pulse therapy; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5378
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids. Abstract : Fulminant myocarditis is an adverse event associated with the COVID‐19 mRNA vaccination. Steroid pulse therapy may control the pathology of myocarditis caused by COVID‐19 mRNA vaccination.